Pharming is a portmanteau of farming and "pharmaceutical" and refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming or biopharming.
The products of pharming are recombinant proteins or their metabolic products. Recombinant proteins are most commonly produced using bacteria or yeast in a bioreactor, but pharming offers the advantage to the producer that it does not require expensive infrastructure, and production capacity can be quickly scaled to meet demand, at greatly reduced cost.
- 1 History
- 2 Pharming in mammals
- 3 Pharming in plants
- 4 Regulation
- 5 Controversy over pharming
- 6 List of originators (companies and universities) and research projects and products
- 7 See also
- 8 References
- 9 Further reading
- 10 External links
The first recombinant plant-derived protein (PDP) was human serum albumin, initially produced in 1990 in transgenic tobacco and potato plants. Open field growing trials of these crops began in the United States in 1992 and have taken place every year since. While the United States Department of Agriculture has approved planting of pharma crops in every state, most testing has taken place in Hawaii, Nebraska, Iowa, and Wisconsin.
In the early 2000s, the pharming industry was robust. Proof of concept has been established for the production of many therapeutic proteins, including antibodies, blood products, cytokines, growth factors, hormones, recombinant enzymes and human and veterinary vaccines. By 2003 several PDP products for the treatment of human diseases were under development by nearly 200 biotech companies, including recombinant gastric lipase for the treatment of cystic fibrosis, and antibodies for the prevention of dental caries and the treatment of non-Hodgkin's lymphoma.
Several proteins were brought to market as research and bioproduction reagents, mostly by Sigma-Aldrich. ProdiGene struck agreements with Sigma to distribute ProdiGene's corn-produced aprotinin, trypsin, beta-glucuronidase (GUS), and avidin. Large Scale Biology and SIgma agreed that Sigma would distribute LSBC's tobacco-produced aprotinin. Sigma also agreed to distribute Ventria's rise-produced Lactoferrin and Lysozyme.
However, in late 2002, just as ProdiGene was ramping up production of trypsin for commercial launch it was discovered that volunteer plants (leftover from the prior harvest) of one of their GM corn products were harvested with the conventional soybean crop later planted in that field. ProdiGene was fined $250,000 and ordered by the USDA to pay over $3 million in cleanup costs. This raised a furor and set the pharming field back, dramatically. Many companies went bankrupt as companies faced difficulties getting permits for field trials and investors fled. In reaction, APHIS introduced more strict regulations for pharming field trials in the US in 2003. In 2005, Anheuser-Busch threatened to boycott rice grown in Missouri because of plans by Ventria Bioscience to grow pharm rice in the state. A compromise was reached, but Ventria withdrew its permit to plant in Missouri due to unrelated circumstances.
The industry has slowly recovered, by focusing on pharming in simple plants grown in bioreactors and on growing GM crops in greenhouses. Some companies and academic groups have continued with open-field trials of GM crops that produce drugs. In 2006 Dow AgroSciences received USDA approval to market a vaccine for poultry against Newcastle disease, produced in plant cell culture - the first plant-produced vaccine approved in the U.S.
Pharming in mammals
Milk is presently the most mature system to produce recombinant proteins from transgenic organisms. Blood, egg white, seminal plasma, and urine are other theoretically possible systems, but all have drawbacks. Blood, for instance, as of 2012 cannot store high levels of stable recombinant proteins, and biologically active proteins in blood may alter the health of the animals. Expression in the milk of a mammal, such as a cow, sheep, or goat, is a common application, as milk production is plentiful and purification from milk is relatively easy. Hamsters and rabbits have also been used in preliminary studies because of their faster breeding.
One approach to this technology is the creation of a transgenic mammal that can produce the biopharmaceutical in its milk (or blood or urine). Once an animal is produced, typically using the pronuclear microinjection method, it becomes efficacious to use cloning technology to create additional offspring that carry the favorable modified genome. In February 2009 the US FDA granted marketing approval for the first drug to be produced in genetically modified livestock. The drug is called ATryn, which is antithrombin protein purified from the milk of genetically modified goats. Marketing permission was granted by the European Medicines Agency in August 2006.
Patentability issues regarding pharming
As indicated above, some mammals typically used for food production (such as goats, sheep, pigs, and cows) have been modified to produce non-food products, a practice sometimes called pharming. Use of genetically modified goats has been approved by the FDA and EMA to produce ATryn, i.e. recombinant antithrombin, an anticoagulant protein drug. These products "produced by turning animals into drug-manufacturing 'machines' by genetically modifying them" are sometimes termed biopharmaceuticals.
The patentability of such biopharmaceuticals and their process of manufacture is uncertain. Probably, the biopharmaceuticals themselves so made are unpatentable, assuming that they are chemically identical to the preexisting drugs that they imitate. Several 19th century United States Supreme Court decisions hold that a previously known natural product manufactured by artificial means cannot be patented. An argument can be made for the patentability of the process for manufacturing a biopharmaceutical, however, because genetically modifying animals so that they will produce the drug is dissimilar to previous methods of manufacture; moreover, one Supreme Court decision seems to hold open that possibility.
On the other hand, it has been suggested that the recent Supreme Court decision in Mayo v. Prometheus may create a problem in that, in accordance with the ruling in that case, "it may be said that such and such genes manufacture this protein in the same way they always did in a mammal, they produce the same product, and the genetic modification technology used is conventional, so that the steps of the process 'add nothing to the laws of nature that is not already present.' " If the argument prevailed in court, the process would also be ineligible for patent protection. This issue has not yet been decided in the courts.
Pharming in plants
Plant-Made Pharmaceuticals (PMPs), also referred to as pharming, is a sub-sector of the biotechnology industry that involves the process of genetically engineering plants so that they can produce certain types of therapeutically important proteins and associate molecules such as peptides and secondary metabolites. The proteins and molecules can then be harvested and used to produce pharmaceuticals.
Recently, several non-crop plants such as the duckweed Lemna minor or the moss Physcomitrella patens have shown to be useful for the production of biopharmaceuticals. These frugal organisms can be cultivated in bioreactors (as opposed to being grown in fields), secrete the transformed proteins into the growth medium and, thus, substantially reduce the burden of protein purification in preparing recombinant proteins for medical use. In addition, both species can be engineered to cause secretion of proteins with human patterns of glycosylation, an improvement over conventional plant gene-expression systems. Biolex Therapeutics developed a duckweed-based expression platform; it sold that business to Synthon and declared bankruptcy in 2012.
Additionally, an Israeli company, Protalix, has developed a method to produce therapeutics in cultured transgenic carrot or tobacco cells. Protalix and its partner, Pfizer, received FDA approval to market its drug, Taliglucerase alfa (Elelyso), treatment for Gaucher's Disease, in 2012.
Arabidopsis is often used as a model organism to study gene expression in plants, while actual production may be carried out in maize, rice, potatoes, tobacco, flax or safflower. The advantage of rice and flax is that they are self-pollinating, and thus gene flow issues (see below) are avoided. However, human error could still result in pharm crops entering the food supply. Using a minor crop such as safflower or tobacco, avoids the greater political pressures and risk to the food supply involved with using staple crops such as beans or rice. Despite these risks, corn and soybeans are currently the most common crops that are being used in field trials to produce pharmaceuticals.
The regulation of genetic engineering concerns the approaches taken by governments to assess and manage the risks associated with the development and release of genetically modified crops. There are differences in the regulation of GM crops - including those used for pharming - between countries, with some of the most marked differences occurring between the USA and Europe. Regulation varies in a given country depending on the intended use of the products of the genetic engineering. For example, a crop not intended for food use is generally not reviewed by authorities responsible for food safety.
Controversy over pharming
There are controversies around GMOs generally on several levels, including whether making them is ethical, issues concerning intellectual property and market dynamics; environmental effects of GM crops; and GM crops' role in industrial agricultural more generally. There are also specific controversies around pharming.
Plants do not carry pathogens that might be dangerous to human health. Additionally, on the level of pharmacologically active proteins, there are no proteins in plants that are similar to human proteins. On the other hand, plants are still sufficiently closely related to animals and humans that they are able to correctly process and configure both animal and human proteins. Their seeds and fruits also provide sterile packaging containers for the valuable therapeutics and guarantee a certain storage life.
Global demand for pharmaceuticals is at unprecedented levels. Expanding the existing microbial systems, although feasible for some therapeutic products, is not a satisfactory option on several grounds. Many proteins of interest are too complex to be made by microbial systems or by protein synthesis. These proteins are currently being produced in animal cell cultures, but the resulting product is often prohibitively expensive for many patients. For these reasons, science has been exploring other options for producing proteins of therapeutic value.
These pharmaceutical crops could become extremely beneficial in developing countries. The World Health Organization estimates that nearly 3 million people die each year from vaccine preventable disease, mostly in Africa. Diseases such as measles and hepatitis lead to deaths in countries where the people cannot afford the high costs of vaccines, but pharm crops could help solve this problem.
While molecular farming is one application of genetic engineering, there are concerns that are unique to it. In the case of genetically modified (GM) foods, concerns focus on the safety of the food for human consumption. In response, it has been argued that the genes that enhance a crop in some way, such as drought resistance or pesticide resistance, are not believed to affect the food itself. Other GM foods in development, such as fruits designed to ripen faster or grow larger, are believed not to affect humans any differently from non-GM varieties.
In contrast, molecular farming is not intended for crops destined for the food chain. It produces plants that contain physiologically active compounds that accumulate in the plant’s tissues. Considerable attention is focused, therefore, on the restraint and caution necessary to protect both consumer health and environmental biodiversity.
The fact that the plants are used to produce drugs alarms activists. They worry that once production begins, the altered plants might find their way into the food supply or cross-pollinate with conventional, non-GM crops. These concerns have historical validation from the ProdiGene incident, and from the StarLink incident, in which GMO corn accidentally ended up in commercial food products. Activists also are concerned about the power of business. According to the Canadian Food Inspection Agency, in a recent report, says that U.S. demand alone for biotech pharmaceuticals is expanding at 13 percent annually and to reach a market value of $28.6 billion in 2004. Pharming is expected to be worth $100 billion globally by 2020.
List of originators (companies and universities) and research projects and products
Please note that this list is by no means exhaustive.
- Dow AgroSciences - poultry vaccine against Newcastle disease virus (first PMP to be approved for marketing by the USDA Center for Veterinary Biologics Dow never intended to market the vaccine. "'Dow Agrosciences used the animal vaccine as an example to completely run through the process. A new platform needs to be approved, which can be difficult when authorities get in contact with it for the first time', explains the plant physiologist Stefan Schillberg, head of the Molecular Biology Division at the Fraunhofer Institute for Molecular Biology and Applied Ecology Aachen."
- Fraunhofer Institute for Molecular Biology and Applied Ecology, with sites in Germany, the US, and Chile is the lead institute of the Pharma Planta consortium of 33 partner organizations from 12 European countries and South Africa, funded by the European Commission. Pharma Planta is developing systems for plant production of proteins in greenhouses in the European regulatory framework. It is collaborating on biosimilars with Plantform and PharmaPraxis (see below).
- Genzyme - antithrombin III in goat milk
- GTC Biotherapeutics - ATryn (recombinant human antithrombin) in goat milk
- Icon Genetics produces therapeutics in transiently infected Nicotiana benthamiana (relative of tobacco) plants in greenhouses in Halle, Germany or in fields. First product is a vaccine for a cancer, non-Hodgkin's lymphoma.
- Iowa State University - immunogenic protein from E. coli bacteria in pollen-free corn as a potential vaccine against E. coli for animals and humans
- Kentucky Bioprocessing took over Large Scale Biology's facilities in Owensboro, Kentucky, and offers contract biomanufacturing services in tobacco plants, grown in greenhouses or in open fields.
- Medicago Inc. - Pre-clinical trials of Influenza vaccine made in transiently infected Nicotiana benthamiana (relative of tobacco) plants in greenhouses Medicago has a system for pharming in alfalfa that their website says is "not suited for the production of vaccines"
- PharmaPraxis - Developing biosimilars in collaboration with PlantForm (see below) and Fraunhofer.
- Pharming - C1 inhibitor, human collagen 1, fibrinogen (with American Red Cross), and lactoferrin in cow milk The intellectual property behind the fibrinogen project was acquired from PPL Therapeutics when PPL went bankrupt in 2004.
- Phyton Biotech uses plant cell culture systems to manufacture active pharmaceutical ingredients based on taxanes, including paclitaxel and docetaxel
- Planet Biotechnology - antibodies against Streptococcus mutans, antibodies against doxorubicin, and ICAM 1 receptor in tobacco
- PlantForm Corporation - biosimilar trastuzumab in tobacco - It is developing biosimilars in collaboration with PharmaPraxis (see above) and Fraunhofer.
- ProdiGene - was developing several proteins, including aprotinin, trypsin and a veterinary TGE vaccine in corn. Was in process of launching trypsin product in 2002 when later that year its field test crops contaminated conventional crops. Unable to pay the $3 million cost of the cleanup, it was purchased by International Oilseed Distributors in 2003 International Oilseed Distributors is controlled by Harry H. Stine, who owns one of the biggest soybeans genetics companies in the US. ProdiGene's maize-produced trypsin, with the trademark TrypZean is currently sold by Sigma-Aldritch as a research reagent.
- Syngenta - Beta carotene in rice (this is "Golden rice 2"), which Syngenta has donated to the Golden Rice Project
- University of Arizona - Hepatitis C vaccine in potatoes
- Ventria Bioscience - lactoferrin and lysozyme in rice
- Washington State University - lactoferrin and lysozyme in barley
- European COST Action on Molecular Farming - COST Action FA0804 on Molecular Farming provides a pan European coordination centre, connecting academic and government institutions and companies from 23 countries. The aim of the Action is to advance the field by encouraging scientific interactions, providing expert opinion and encouraging commercial development of new products. The COST Action also provides grants allowing young scientists to visit participating laboratories across Europe for scientific training.
- Mapp Biopharmaceutical in San Diego, California was reported in August 2014 to be developing ZMapp, an experimental cure for the deadly Ebola virus disease. Two Americans who had been infected in Liberia were reported to be improving with the drug. ZMapp was made using antibodies produced by GM tobacco plants.
Projects known to be abandoned
- Agragen, in collaboration with University of Alberta - docosahexaenoic acid and human serum albumin in flax
- Chlorogen, Inc. - cholera, anthrax, and plague vaccines, albumin, interferon for liver diseases including hepatitis C, elastin, 4HB, and insulin-like growth factor in tobacco chloroplasts. Went out of business in 2007.
- Dow Chemical Company made a deal with Sunol Molecular in 2003 to develop antibodies against tissue factor in plants and in mammalian cell culture and to compare them. In 2005 Sunol sold all its tissue factor antagonists to Tanox, which in turn was bought by Genentech in 2003. Genentech licensed the tissue factor program to Altor in 2008 Altor is itself a spinout from Sunol. The product under development, ALT-836, formerly known as TNX-832 and Sunol-cH36, is the not the plant-produced antibody, but rather is mammalian antibody, more specifically, a chimeric antibody produced in a hybridoma.
- Epicyte - spermicidal antibodies in corn Epicyte was purchased by Biolex in 2004 at which time Epicyte's portfolio was described as "focused on the discovery and development of human monoclonal antibody products as treatments for a wide range of infectious and inflammatory diseases."
- Large Scale Biology Corporation (LSBC) (bankrupt) - used Tobacco mosaic virus to develop reagents and patient-specific vaccines for Non-Hodgkin's lymphoma, Papillomavirus vaccine, parvovirus vaccine, alpha galactosidase for Fabry disease, lysosomal acid lipase, aprotinin, interferon Alpha 2a and 2b, G-CSF, and Hepatitis B vaccine antigens in tobacco. In 2004, LSBC announced an agreement with Sigma-Aldritch under which LSB would produce recombinant aprotinin in plants of the tobacco family and Sigma-Aldrich would commercially distribute LSBC's recombinant product to its customers in the R&D, cell culture and manufacturing markets. As of October 2012 SIgma still has the protein in stock.
- Meristem Therapeutics - Lipase, lactoferrin, plasma proteins, collagen, antibodies (IgA, IgM), allergens and protease inhibitors in tobacco. Liquidated in 2008.
- Novoplant GmgH - therapeutic proteins in tobacco and feed peas. Conducted field trials in US of feed peas for pigs that produced anti-bacterial antibodies. Former CSO is now with another company; appears that Novoplant is out of business.
- Monsanto Company - abandoned development of pharmaceutical producing corn
- PPL Therapeutics - Alpha 1-antitrypsin for cystic fibrosis and emphysema in sheep milk. This is the company that created Dolly the Sheep, the first cloned animal. Went bankrupt in 2004. Assets were acquired by Pharming and an investment group including University of Pittsburgh Medical Center.
- SemBioSys - insulin in safflower. In May 2012, SemBioSys terminated its operations.
- Genetically modified organism
- Polly and Molly
- International Center for Technology Assessment
- Quinion, Michael. "Molecular farming". World Wide Words. Retrieved 2008-09-11.
- Norris, Sonya (4 July 2005). "Molecular farming". Library of Parliament. Parliament of Canada. PRB 05-09E. Retrieved 2008-09-11.
- Humphreys, John M; Chapple, Clint (2000). "Molecular 'pharming' with plant P450s". Trends Plant Sci. 5 (7): 271–2. doi:10.1016/S1360-1385(00)01680-0. PMID 10871897.
- Miller, Henry I. (2003). "Will we reap what biopharming sows?". Commentary. Nat. Biotechnol. 21 (5): 480–1. doi:10.1038/nbt0503-480. PMID 12721561.
- Kaiser, Jocelyn (25 April 2008). "Is the Drought Over for Pharming?" (PDF). Science 320 (5875): 473–5. doi:10.1126/science.320.5875.473. PMID 18436771.
- Sijmons, Peter C.; Dekker, Ben M. M.; Schrammeijer, Barbara et al. (1990). "Production of Correctly Processed Human Serum Albumin in Transgenic Plants". Bio/Technology 8 (3): 217–21. doi:10.1038/nbt0390-217. PMID 1366404.
- Kimbrell, Andrew (2007). Your right to know: Genetic engineering and the secret change in your food. California: Earth Aware Editions. OCLC 74353733.[page needed]
- Twyman, Richard M.; Stoger, Eva; Schillberg, Stefan et al. (2003). "Molecular farming in plants: Host systems and expression technology". Trends Biotechnol. 21 (12): 570–8. doi:10.1016/j.tibtech.2003.10.002. PMID 14624867.
- Ma, Julian K-C.; Drake, Pascal M. W.; Christou, Paul (2003). "Genetic modification: The production of recombinant pharmaceutical proteins in plants". Nature Reviews Genetics 4 (10): 794–805. doi:10.1038/nrg1177. PMID 14526375.
- SIgma Info Sheet
- "ProdiGene Launches First Large Scale-Up Manufacturing of Recombinant Protein From Plant System" (Press release). ProdiGene. February 13, 2002. Retrieved March 8, 2013.
- News of contamination[unreliable source?]
- Biotechnology Regulatory Services Factsheet [Internet]: US Department of Agriculture; c2006. Available from: http://www.aphis.usda.gov/publications/biotechnology/content/printable_version/BRS_FS_pharmaceutical_02-06.pdf
- Boehm, Robert (2007). "Bioproduction of Therapeutic Proteins in the 21st Century and the Role of Plants and Plant Cells as Production Platforms". Annals of the New York Academy of Sciences 1102: 121–34. doi:10.1196/annals.1408.009. PMID 17470916.
- FDA Approval News
- Ma, Julian K -C.; Barros, Eugenia; Bock, Ralph; Christou, Paul; Dale, Philip J.; Dix, Philip J.; Fischer, Rainer; Irwin, Judith et al. (2005). "Molecular farming for new drugs and vaccines". EMBO reports 6 (7): 593–9. doi:10.1038/sj.embor.7400470. PMC 1369121. PMID 15995674.
- Houdebine, Louis-Marie (2009). "Production of pharmaceutical proteins by transgenic animals". Comparative Immunology, Microbiology and Infectious Diseases 32 (2): 107–21. doi:10.1016/j.cimid.2007.11.005. PMID 18243312.
- Dove, Alan (2000). "Milking the genome for profit". Nature Biotechnology 18 (10): 1045–8. doi:10.1038/80231. PMID 11017040.
- Staff (2008) FDA Approves First Human Biologic Produced by GE Animals US Food and Drug Administration, from the FDA Vetenarian Newsletter 2008 Volume XXIII, No VI, Retrieved 10 December 2012
- "Go-ahead for 'pharmed' goat drug". BBC News. June 2, 2006. Retrieved 2006-10-25.
- Andre Pollack for the New York Times. February 6, 2009 F.D.A. Approves Drug From Gene-Altered Goats
- Richard H. Stern. Mayo v Prometheus: No Patents on Conventional Implementations of Natural Principles and Fundamental Truths,  Eur. Intell. Prop. Rev. 502, 517. See Cochrane v. Badische Anili11 & Soda Fabrik, 111 U.S. 293, 311 (1884) (holding invalid claim to artificially made plant dye; "the product itself could not be patented, even though it was a product made artificially for the first time"); American Wood-Paper Co. v. Fibre Disintegrating Co., 90 U.S. 566, 596 (1874) (holding invalid claim to artificially manufactured paper-pulp because "whatever may be said of their process for obtaining it, the product was in no sense new").
- The American Wood-Paper case invalidated the product patent but left open the patentability of the process, saying "whatever may be said of their process for obtaining it...." 90 U.S. at 596.
- Mayo Collaborative Services v. Prometheus Labs., Inc., 566 U.S. __, 132 S. Ct. 1289 (2012).
- Richard H. Stern. Mayo v Prometheus: No Patents on Conventional Implementations of Natural Principles and Fundamental Truths,  Eur. Intell. Prop. Rev. 502, 517-18 (quoting Mayo v. Prometheus; see also Alice v. CLS Bank, 573 U.S. __, 134 S. Ct. 2347 (2014) (to similar effect).
- Büttner-Mainik, Annette; Parsons, Juliana; Jérôme, Hanna; Hartmann, Andrea; Lamer, Stephanie; Schaaf, Andreas; Schlosser, Andreas; Zipfel, Peter F.; Reski, Ralf (2011). "Production of biologically active recombinant human factor H in Physcomitrella". Plant Biotechnology Journal 9 (3): 373–83. doi:10.1111/j.1467-7652.2010.00552.x. PMID 20723134.
- Gasdaska, John R.; Spencer, David; Dickey, Lynn (2003). "Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna". BioProcessing Journal 2 (2): 49–56.
- Baur, Armin; Reski, Ralf; Gorr, Gilbert (2005). "Enhanced recovery of a secreted recombinant human growth factor using stabilizing additives and by co-expression of human serum albumin in the moss Physcomitrella patens". Plant Biotechnology Journal 3 (3): 331–40. doi:10.1111/j.1467-7652.2005.00127.x. PMID 17129315.
- Cox, Kevin M; Sterling, Jason D; Regan, Jeffrey T; Gasdaska, John R; Frantz, Karen K; Peele, Charles G; Black, Amelia; Passmore, David; Moldovan-Loomis, Cristina (2006). "Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor". Nature Biotechnology 24 (12): 1591–7. doi:10.1038/nbt1260. PMID 17128273.
- Decker, Eva L.; Reski, Ralf (2007). "Current achievements in the production of complex biopharmaceuticals with moss bioreactors". Bioprocess and Biosystems Engineering 31 (1): 3–9. doi:10.1007/s00449-007-0151-y. PMID 17701058.
- Protalix website - technology platform
- Gali Weinreb and Koby Yeshayahou for Globes May 2, 2012. FDA approves Protalix Gaucher treatment
- "Molecular Farming – Plant Bioreactors". BioPro. Retrieved 2008-09-13.
- Thomson, JA (2006). Seeds for the future: The impact of genetically modified crops on the environment. Australia: Cornell University Press.[page needed]
- Mandel, Charles (2001-11-06). "Molecular Farming Under Fire". wired. Retrieved 2008-09-13.
- "Protein Products for Future Global Good". molecularfarming.com. Retrieved 2008-09-11.
- Retrieved on 15 May 2007
- Margret Engelhard, Kristin Hagen, Felix Thiele (eds). (2007) Pharming A New Branch of Biotechnology 
- Farming for Pharma
- Frauenhofer website
- Pharma Planta website
- FAQ page
- Brennan, Zachary. Brazilian JV looks to tap plant-based manufacturing system for biosimilars. BioPharma-Reporter.com, 23-Jul-2014.
- GTC website
- Press release on opening Halle facility
- Icon press release on clinical trial launch
- Iowa State Ag School 2006 Newsletter
- APHIS approval
- Iowa State plant scientists tweak their biopharmaceutical corn research project
- Kentucky Bioprocessing website
- Vezina, Louis-P.; D'Aoust, Marc Andre; Landry, Nathalie; Couture, Manon M.J.; Charland, Nathalie; Barbeau, Brigitte; Sheldon, Andrew J. (2011). "Plants As an Innovative and Accelerated Vaccine-Manufacturing Solution". BioPharm International Supplements 24 (5): s27–30.
- Alfalfa page on Medicago website
- Company website
- Press on Pharming Purchase of PPL assets
- Phyton Biotech Official Website
- Company website
- Company website
- Press release from internet archive
- Bloomberg BusinessWeek Profile
- Stine Seeds Website
- Trademark listing
- Ray, Kevin; Jalili, Pegah R. (2011). "Characterization of TrypZean: a Plant-Based Alternative to Bovine-Derived Trypsin (Peer-Reviewed)". BioPharm International 24 (10): 44–8.
- Sigma Catalog
- FAQ page
- Arntzen website at UofA
- Khamsi, Roxanne (2005). "Potatoes pack a punch against hepatitis B". News@nature. doi:10.1038/news050214-2.
- "NEPA Decision Summary for Permit #10-047-102r" (PDF). Animal and Plant Health Inspection Service. March 10, 2010.
- Wettstein lab webpage
- COST Action FA0804 Official Website
- Ward, Andrew (8 August 2014) Biotech groups face ethical dilemmas in race for Ebola Cure, Financial Times, Page 4, Internet article retrieved 8 August 2014
- Langreth, Robert, et al (5 August 2014) Ebola Drug Made From Tobacco Plant Saves U.S. Aid Workers Bloomberg News, Retrieved 8 August 2014
- Published PCT Application
- CEO Sam Huttenbauer testified before Congress in 2005 about their GM flax efforts Testimony
- Web search on October 6, 2012 found no website for this company and found that executives are all with other companies.
- Bloomberg BusinessWeek Profile
- Plant production for cancer protein Sept 22, 2003
- Press Release
- Purchase contract
- Press Release
- Altor website
- Clinical trial number NCT00879606 for "Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome" at ClinicalTrials.gov
- Jiao, J.-a.; Kelly, A. B.; Marzec, U. M.; Nieves, E.; Acevedo, J.; Burkhardt, M.; Edwards, A.; Zhu, X.-y.; Chavaillaz, P.-A. (2009). "Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site". Thrombosis and Haemostasis 103 (1): 224–33. doi:10.1160/TH09-06-0400. PMC 2927860. PMID 20062929.
- Guardian report Sept 2001
- Trelys press release
- Lamb, Celia (2006-01-13). "Large Scale files Ch. 11 after closing". Sacramento Business Journal. Retrieved 2007-05-10.
- Biomanufacturing Press Release
- Sigma catalog Aprotinin
- History of bankrupt biotech companies
- Cordis entry on Novoplant
- APHIS approval
- Kiprijanov biography
- UPMC buys PPL assets
- Press release May 15, 2012: SemBioSys Announces First Quarter Results and Provides Update on Activities
- Biotech firm puts off rice crop here But company says it plans to sow next year. St. Louis Post-Dispatch. April 29, 2005. Pg. A3.
- Biotech potato provides hepatitis vaccine. The Atlanta Journal-Constitution. February 15, 2005. Pg. 3A.
- Biotechnology Venture Hits Unexpected Snags. New York Times. November 23, 2001. Pg. 5.
- Canadian scientists make insulin from plants: 'Bio-pharming' poised to meet huge diabetes demand at less cost. The Ottawa Citizen. February 27, 2005. Pg. A1.
- GM corn set to stop man spreading his seed. The Observer. September 9, 2001. Pg. 1.
- Pharming plans transgenic first. Financial Times. May 3, 2005. Pg. 18.
- USDA says bio-crop safeguards are tighter ProdiGene is back in Nebraska with test plot. Omaha World Herald. June 2, 2004 Pg. 01D
- Release Permits for Pharmaceuticals, Industrials,Value Added Proteins for Human Consumption,or for Phytoremediation Granted or Pending by APHIS as of March 29, 2006. 
- molecularfarming.com Official site
- Molecular Farming – Plant Bioreactors
- Moss bioreactors do not smell (Interview with Ralf Reski)
- Molecular Pharming - pharmaceuticals with the help of GM plants
- Pharming for Farmaceuticals
- "Pharming the Field: A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals". The Pew Charitable Trusts. July 18, 2002.
- USDA-APHIS Biotechnology Regulatory Services
- EPA Biotechnology page
- FDA Biotechnology page
- Homepage of the Coordinated Framework for Regulation of Biotechnology
- Draft Guidance for APHIS Permits for Field Testing or Movement of Organisms with Pharmaceutical or Industrial Intent
- PlantPharma.org Online Community
- National Science Foundation
- Pharma-Planta Consortium
- Biotechnology Industry Organization
- Society for Moleculture, a non-for-profit organisation for plant- factories, Québec, Canada